Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced promising clinical data from investigator-sponsored studies of ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, FOLOTYN® (pralatrexate injection), and belinostat, Spectrum’s novel histone deacetylase (HDAC) inhibitor. As reported in poster presentations at the recent 54th Annual Meeting of the American Society of Hematology (ASH), studies of ZEVALIN showed promising results in diverse settings and potential indications, including first-line consolidation in patients with diffuse large B-cell lymphoma (DLBCL); treatment of elderly patients with non-Hodgkin’s lymphoma (NHL), and new drug combinations to treat follicular non-Hodgkin’s lymphoma (fNHL). In addition, preclinical
research showed promising synergistic, anti-tumor activity of FOLOTYN, while a Phase 1 study demonstrated early evidence of activity of belinostat in combination therapy of patients, including those with relapsed or refractory acute leukemia.
“This year’s ASH meeting was another important conference for Spectrum, both because of the number of presentations – 12 for ZEVALIN, 3 for FOLOTYN and 4 for belinostat – and the high quality of the data,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “Members of the Eastern Cooperative Oncology Group, Sunnybrook Health Sciences Centre in Toronto and other key institutions around the world have reported findings that can help expand our understanding of ZEVALIN in specific patient groups, as well as in potential new applications and in combination with other therapies. Further, we are pleased with the reports from studies testing combination regimens that incorporate either FOLOTYN or belinostat, demonstrating research interest in potential synergies, especially for hard-to-treat diseases.”
Spectrum's R&D program for ZEVALIN includes, among other initiatives, two Phase 3 studies that are sponsored or funded by the Company: the Phase 3 ZEST trial for first-line consolidation in patients with newly diagnosed DLBCL and the investigator-sponsored Phase 3 SPINOZA trial for patients with aggressive lymphoma who receive autologous stem cell transplantation (ASCT).